MedTrace Logo

Rituximab in Refractory Primary Membranous Nephropathy

NCT03880643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2019-11-13

No results posted yet for this study

Summary

Primary membranous nephropathy (PMN), an autoimmune disease mostly associated with anti-phospholipase-A2-receptor (PLA2R) antibodies, is one of the most common causes of nephrotic syndrome in adults. In 30% to 40% of all cases, patients with PMN undergo spontaneous remission with conservative approaches. Corticosteroids, alkylating agents and calcineurin inhibitors are recommended treatment options in persistent disease activity despite supportive therapies. Nevertheless, patients with refractory disease constitute an important clinical aspect of PMN, and uncontrolled proteinuria may culminate in rapid progression to end-stage renal disease. In recent years, several studies demonstrated the efficacy of rituximab as a treatment option in patients with refractory PMN; however, data regarding daily clinical practice of this agent is still needed. Therefore, we conducted a study using our registry data to evaluate the efficacy and safety of rituximab in patients with refractory PMN.

Conditions

  • Glomerulonephritis, Membranous

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Halil Yazici, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

  • Safak Mirioglu, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-05-31
Completion
2019-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880643 on ClinicalTrials.gov